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Abstract
Background
Mass azithromycin distributions have been shown to reduce mortality among pre-school
children in sub-Saharan Africa. It is unclear what mediates this mortality reduction, but one
possibility is that antibiotics function as growth promoters for young children.
Methods and findings
24 rural Ethiopian communities that had received biannual mass azithromycin distributions
over the previous four years were enrolled in a parallel-group, cluster-randomized trial.
Communities were randomized in a 1:1 ratio to either continuation of biannual oral azithro-
mycin (20mg/kg for children, 1 g for adults) or to no programmatic antibiotics over the 36
months of the study period. All community members 6 months and older were eligible for the
intervention. The primary outcome was ocular chlamydia; height and weight were measured
as secondary outcomes on children less than 60 months of age at months 12 and 36. Study
participants were not masked; anthropometrists were not informed of the treatment alloca-
tion. Anthropometric measurements were collected for 282 children aged 0–36 months at
the month 12 assessment and 455 children aged 0–59 months at the month 36 assessment,
including 207 children who had measurements at both time points. After adjusting for age
and sex, children were slightly but not significantly taller in the biannually treated communi-
ties (84.0 cm, 95%CI 83.2–84.8, in the azithromycin-treated communities vs. 83.7 cm, 95%
CI 82.9–84.5, in the untreated communities; mean difference 0.31 cm, 95%CI -0.85 to 1.47,
P = 0.60). No adverse events were reported.
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Conclusions
Periodic mass azithromycin distributions for trachoma did not demonstrate a strong impact
on childhood growth.
Trial registration
The TANA II trial was registered on clinicaltrials.gov #NCT01202331.
Author summary
Mass distribution of a single dose of the broad-spectrum antibiotic azithromycin twice
per year to pre-school children in Sub-Saharan Africa has been shown to reduce child-
hood mortality. The mechanism by which azithromycin reduces mortality is currently not
clear, especially since the antibiotic is not targeted to sick children but rather given to all
children in the community whether or not they have an infectious disease. In this study,
we report the height and weight of children enrolled in a trial in Ethiopia in which com-
munities were randomized either to twice annual mass azithromycin distributions for
blinding trachoma or to no treatments. After accounting for age and sex, children from
azithromycin-treated communities were on average slightly taller at the 12- and 36-month
study visits than those from untreated communities, but the difference was not statistically
significant.
Introduction
Undernutrition is thought to contribute more to the global burden of disease than any other
risk factor.[1] Poor nutrition potentiates the effects of infections such as diarrhea, respiratory
infections, and malaria, leading to worse outcomes and higher mortality.[2, 3] Infectious dis-
eases in turn lead to poor growth.[4] It is conceivable that antibiotics could have an important
role for breaking this cycle of malnutrition and infection. For example, a randomized trial
demonstrated less stunting and underweight in HIV-infected children who took daily co-tri-
moxazole compared to those taking placebo.[5] This idea is not new; antibiotics have long
been thought to be effective growth promoters for animal husbandry.[6]
Mass azithromycin treatments have recently been shown to reduce childhood mortality in
sub-Saharan Africa, although the causal pathway for the mortality reduction is unclear.[7, 8]
Azithromycin is a broad-spectrum antibiotic with efficacy against a wide array of pathogens
that cause respiratory disease, diarrhea, and malaria, so it is possible that azithromycin pre-
vents mortality by directly clearing these infections.[9–11] Alternatively, if azithromycin
caused height and weight gain in children, it is possible that the improved growth could be
partly responsible for the survival benefit.
In a recent cluster-randomized trial, we randomized communities that had been treated
with four years of mass azithromycin for trachoma to either continued antibiotics or cessation
of treatment. Cluster-randomization, which was chosen for the primary trachoma outcomes,
allowed assessment of both the direct and spillover effects of antibiotics.[12] We recognized
that this trial provided an opportunity to assess whether mass azithromycin distributions had
an effect on childhood growth, and consequently added height and weight as secondary out-
comes. We compared anthropometric measurements at the individual level to determine
whether mass azithromycin increased childhood growth.
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Methods
Ethics
The study had approval from the University of California, San Francisco; Emory University;
the Ethiopian Ministry of Science and Technology; and the Food, Medicine, and Health Care
Administration and Control Authority of Ethiopia. The study was carried out in accordance
with the Declaration of Helsinki and overseen by a Data Safety and Monitoring Committee
appointed by the National Institutes of Health-National Eye Institute. Verbal informed con-
sent was obtained in Amharic from community leaders before randomization and from the
guardians of all children post-randomization; verbal consent was approved by all institutional
review boards and was used due to the high levels of illiteracy in the study area.
Study design
This study describes a secondary outcome from a parallel-group cluster-randomized clinical
trial for trachoma (TANA II; clinicaltrials.gov #NCT01202331) performed in the Goncha Siso
Enese woreda (district) of the Amhara region in Ethiopia.[13] The trial was conducted in com-
munities that had been treated with 8 biannual mass azithromycin distributions for trachoma as
part of an earlier trial (TANA I; clinicaltrials.gov #NCT00322972).[14] In the initial TANA I
trial (June 2006 until November 2009), 72 contiguous subkebeles (sub-districts) were random-
ized to 1 of 6 different trachoma treatment strategies.[14] Rural subkebeles were eligible for
enrollment if they were located within a 3-hour walk from the farthest point accessible to a
four-wheel drive automobile. As part of the TANA I trial, 12 subkebeles were randomized to
receive biannual mass azithromycin distributions (every 6 months, ±1 month). Each subkebele
consisted of approximately 4–6 government-defined demographic units known as state teams;
all state teams in the subkebele were treated identically. In TANA II (November 2010 until May
2013), two randomly selected state teams from each biannually treated subkebele were random-
ized to either continued biannual mass azithromycin (N = 12 state teams) or cessation of antibi-
otics (N = 12 state teams). Anthropometric indices were measured as a secondary outcome in
these 24 state teams 12 and 36 months after randomization, providing a randomized controlled
trial comparison of childhood growth in communities treated with mass azithromycin distribu-
tions versus no treatment. No changes were made to the anthropometry portion of the study
after its addition to the main trial. The trial was reported according to CONSORT guidelines
(S1 Checklist). Details of the study design were pre-specified in a trial protocol (S1 Protocol).
Randomization and masking
This study employed pair-matched cluster-randomization with matching based on the TANA
I subkebele. A biostatistician (TCP) used the statistical package R (R Foundation for Statistical
Computing, Vienna, Austria) to randomize 12 pairs of state teams from each of 12 subkebeles,
with one member of the pair allocated to intervention and the other to control. A study coordi-
nator enrolled the communities and participants and assigned the intervention. Allocation
was concealed by enrolling all communities before randomization and administering the
intervention to the entire community population. Although study participants were not
masked to their cluster’s treatment assignment, the study personnel responsible for anthropo-
metric assessments were not informed of the treatment allocation or study hypothesis.
Intervention
Local health extension workers performed a population census each year to enumerate all
community members eligible for treatment. Because birthdates are imprecise in this part of
Cluster-randomized trial of mass azithromycin for trachoma: anthropometric outcomes
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Ethiopia, census-takers recorded age in years. During scheduled mass treatment visits, these
same health workers offered a single dose of directly observed oral azithromycin (20mg/kg
height-based approximation for children, 1g for adults) to all community members except for
children under 6 months of age, self-reported pregnant women, and those known to be allergic
to macrolide antibiotics, each of whom were instead offered a six-week course of twice daily
tetracycline ophthalmic ointment. Each community was treated twice per year (Fig 1). Antibi-
otic coverage during mass treatments was assessed from the preceding census. Although study
participants from all communities continued to receive routine government health services
during this time, no other studies or interventions were performed during the study period.
No adverse events were reported through routine passive surveillance activities; active moni-
toring of adverse events was performed during the trial and is reported elsewhere.[15]
Outcome assessment
We performed anthropometric assessments after the month 12 and month 36 treatments. All
children aged 0–59 months identified from the most recent census were offered height and
weight measurements, conducted in a central area in each state team. We recruited anthropo-
metrists from the local communities, and conducted a 2-day training session using methods
recommended by the World Health Organization (WHO). Anthropometry teams demon-
strated high levels of reproducibility for all measurements.[16] We used a portable stadiometer
(Shorr Productions, LLC, Olney, MD, USA) to measure height or length and a Seca 874 floor
scale (Seca GmbH & Co. KG, Hamburg, Germany) to measure weight. Each measurement was
taken in triplicate, with the median used as the official measurement.
Statistics
The pre-specified primary analysis for the anthropometric outcomes was a post-test only com-
parison of height adjusted for age and sex in children not old enough to be eligible for treat-
ment during the first trial (i.e., aged 0–36 months at the 12-month visit and 0–59 months at
the 36-month visit). Repeated measures for height were modeled as a function of treatment
arm, time, age in years (as a continuous variable rounded to whole years), and sex in a mixed
effects linear regression, with state team and individual modeled as random effects. Heteroske-
dasticity was modeled by allowing independent residual errors over each year of age. The p-
value was estimated with a Monte Carlo permutation test stratified by subkebele to account for
the randomization strategy (10,000 permutations of the likelihood ratio comparing models
with and without the treatment term). Intraclass correlation coefficients (ICCs) were calcu-
lated from the model to assess cluster-correlation of the primary outcome. Similar models
were constructed for the secondary underweight analysis (weight adjusted for age and sex).
We purposefully did not use z-scores in the primary analysis given the imprecision of reported
ages in the study area. For all outcomes, we performed intention-to-treat analyses.
Sample size
Sample size calculations for the trial were based on the primary trachoma outcomes and set at
12 communities per arm; including 18 children per community would provide 80% power to
detect a 1 cm difference between the two arms assuming an average height of 90 cm (standard
deviation 10 cm), ICC of 0.02, correlation coefficient of 0.9 for the relationship of height with
age and sex, equal cluster sizes, and a two-sided alpha of 0.05.[17] All analyses were performed
using Stata 14.2 (Statacorp, College Station, TX) except for permutation tests, which were
done in R 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria).
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Results
The study was conducted from November 2010 until May 2013. Characteristics of the two
treatment arms were balanced at baseline (Table 1). The biannual treatment group received 7
mass azithromycin treatments during the continuation trial; the control group received none.
Table 2 shows the median antibiotic coverage at each distribution for the under-5 age group.
We obtained anthropometric measurements on 282 of 387 (73%) eligible children aged <3
years at the 12-month visit and 455 of 591 (77%) eligible children aged<5 years at the
36-month visit, with 207 children having measurements at both visits. As shown in Table 3,
children who were eligible but did not participate in the anthropometric assessment tended to
be younger than those who participated.
The mean height and weight in each treatment arm at the two time points are shown in
Table 4, stratified by age. After adjusting for age, sex, and study visit, the mean height was 84.0
cm (95%CI 83.2–84.8) in the azithromycin-treated communities and 83.7 (95%CI 82.9–84.5)
in the untreated communities. In the primary pre-specified analysis adjusted for age, sex, and
time point, children in the azithromycin-treated communities were on average 0.31 cm taller
(95%CI -0.85 to 1.47) than those in untreated communities (P = 0.60). The ICC derived from
the main statistical model suggested mild clustering of height measurements within communi-
ties (ICC 0.05, 95%CI 0.02 to 0.13).
The weight outcome is summarized in Table 4. After adjusting for age, sex, and study visit,
the average weight was 10.8 kg in the azithromycin-treated communities and 10.7 in the
untreated communities—a non-significant difference (mean weight 0.09 kg heavier in the
azithromycin arm, 95%CI -0.20 to 0.39; P = 0.54; ICC 0.07, 95%CI 0.03 to 0.15). Additional
sensitivity analyses using all<5 year-old children at both outcome visits (i.e., including chil-
dren from the 12-month visit who had been treated in the previous trial) had similar results
(S1 File).
Discussion
We failed to find an association between mass azithromycin distributions and childhood
growth. Although on average children from communities treated with biannual mass azithro-
mycin distributions over a 3-year period were slightly taller than children from untreated
Fig 1. Participant flow. Communities were randomized twice: originally as part of the TANA I trial (2006–2009), and subsequently as part of
TANA II (2010–2013).
https://doi.org/10.1371/journal.pntd.0007442.g001
Table 1. Baseline characteristics of 24 communities randomized to either continuation or cessation of biannual
mass azithromycin treatment.
Biannual MDA
(N = 12 communities)
No MDA
(N = 12 communities)
Persons per community 309 (242–423) 259 (180–360)
Proportion female, % 51.1% (47.6–52.4%) 52.1% (48.6–55.2%)
Proportion <10 years, % 28.3% (26.5–29.5%) 27.2% (25.4–29.8%)
Prevalence of active trachoma, %� 42.1% (13.1–53.6%) 30.9% (20.0–48.9%)
Distance to nearest town, km 8.4 (5.1–9.2) 8.1 (5.0–9.1)
Altitude, m 2622 (2528–2674) 2611 (2545–2657)
Values indicate the median and interquartile range of community-level data. MDA: mass drug administration with
azithromycin
� Sub-district prevalence, as assessed from a random sample of children aged <10 years of age
https://doi.org/10.1371/journal.pntd.0007442.t001
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communities, the differences between the two treatment groups were not consistently statisti-
cally significant across different regression model parameterizations and of small magnitude.
This trial assessed the hypothesis that azithromycin functions as a growth promoting agent
for preschool children. The specific mechanisms through which antibiotics may promote
growth are unknown, though several theories have been proposed.[18] Antibiotics could treat
or prevent infections that would otherwise divert metabolic resources. Antibiotics may also
alter intestinal absorption by clearing pathogenic organisms and changing the composition of
the gut microbiome, both of which may ultimately mitigate the role of bacterial infection in
environmental enteropathy.[19, 20] Alternatively, antibiotics like azithromycin are known to
have direct anti-inflammatory properties, which could potentially affect growth.
It is conceivable that improvements in growth could translate into improved childhood sur-
vival. It is thought that growth and nutrition are important modulators of infectious diseases.
Better nutrition may enhance the ability of the immune system to clear infections, and thus
make a child less susceptible to severe complications of infection. Indeed, growth promotion is
one theory for the improved survival observed following mass azithromycin distributions.[7,
8] While this study does not provide evidence that mass azithromycin impacts childhood
growth, it is still possible that azithromycin treatments affect growth but at a magnitude
Table 2. Azithromycin coverage among population aged 6–59 months of age in 12 biannually treated
communities.
Month No. per community Antibiotic coverage
0 35 (29–44) 86% (83–91%)
6 34 (27–42) 93% (91–94%)
12 29 (21–40) 91% (86–95%)
18 29 (20–42) 91% (89–98%)
24 29 (21–41) 82% (76–86%)
30 28 (21–41) 94% (92–96%)
36 27 (17–41) 87% (83–89%)
Values represent median and interquartile range of community-level data.
https://doi.org/10.1371/journal.pntd.0007442.t002
Table 3. Characteristics of study participants at each monitoring visit, stratified by participation status.
Biannual MDA No MDA
Characteristic Participating Not participating Participating Not participating
Month 12 N = 146 N = 68 N = 136 N = 37
Female 77 (52.7%) 40 (58.8%) 66 (48.5%) 18 (48.7%)
Age
0 y 32 (21.9%) 32 (47.1%) 23 (16.9%) 11 (29.7%)
1 y 62 (42.5%) 17 (25.0%) 50 (36.8%) 10 (27.0%)
2 y 52 (35.6%) 19 (27.9%) 63 (46.3%) 16 (43.2%)
Month 36 N = 235 N = 71 N = 220 N = 65
Female 121 (51.5%) 36 (50.7%) 104 (47.3%) 32 (49.2%)
Age
0 y 15 (6.4%) 11 (15.5%) 15 (6.8%) 7 (10.8%)
1 y 52 (22.1%) 18 (25.4%) 28 (12.7%) 7 (10.8%)
2 y 44 (18.7%) 13 (18.3%) 52 (23.6%) 15 (23.1%)
3 y 64 (27.2%) 17 (23.9%) 62 (28.2%) 19 (29.2%)
4 y 60 (25.5%) 12 (16.9%) 63 (28.6%) 17 (26.2%)
https://doi.org/10.1371/journal.pntd.0007442.t003
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smaller than could be detected by the present study. For example, the results of the present
study are consistent with a meta-analysis that estimated antibiotics to confer an additional 0.04
cm of linear growth per month.[21]
Previous randomized trials have studied the impact of antibiotics on childhood growth in
the context of a specific disease, such as severe acute malnutrition, HIV, diarrhea, cystic fibro-
sis, or vesicoureteral reflux.[22–25] Notable among these is a placebo-controlled trial of daily
prophylactic co-trimoxazole therapy for HIV-infected children in Zambia that found
improved linear growth and decreased mortality in antibiotic-treated children.[5] While many
of the other studies failed to find an effect of antibiotic therapy on height measurements, they
were of relatively short duration and focused on changes in weight instead of height.[22–25]
Other trials have assessed whether community antibiotic distributions affect growth param-
eters. Two placebo-controlled studies performed in Guatemala, one of which treated school-
aged children with aureomycin and another which treated preschool children with metronida-
zole, found improved height and weight metrics in children treated with antibiotics. However,
these studies may be subject to type I error since they allocated a single cluster of children to
the antibiotic intervention but performed analyses at the individual level.[26, 27] Several recent
cluster-randomized trials testing more frequent vs. less frequent mass azithromycin distribu-
tion strategies for trachoma have failed to detect a difference in height or weight between the
different dosing groups.[17, 28, 29] The control groups in those studies were not ideal in that
they too received antibiotics—albeit at lower frequencies—and thus may have received a bene-
fit of antibiotic therapy. The present study is an improvement over these previous reports in
that no programmatic antibiotics were given in the control group, providing a better assess-
ment of the effectiveness of antibiotics alone.
Mass antibiotics provide selection pressure for antibiotic-resistant organisms, which
increases the community prevalence of resistance.[30] Although the clinical importance of
such resistance is unclear given the low usage of macrolide antibiotics in developing countries,
the potential for antibiotic resistance should be taken into account wherever implementation
of mass azithromycin distributions is considered.[31]
Several limitations to this study should be noted. We conducted a post-test only analysis
with two follow-up visits. Baseline and more frequent anthropometric measurements would
have increased the precision and added to the statistical power of the study. Ages were not
known with great accuracy in this study, since families in this region of Ethiopia do not keep
health cards and do not record dates of birth. Imprecision in age could have biased the study if
age was differentially recorded between treatment arms or if cluster-randomization left an
Table 4. Anthropometric assessment stratified by follow-up visit and age.
Biannual Mass Azithromycin No Mass Azithromycin
Age N Height, cm Weight, kg N Height, cm Weight, kg
Month 12
0 y 32 66.6 (65.1–68.1) 7.1 (6.7–7.5) 23 68.1 (65.3–71.0) 7.3 (6.8–7.7)
1 y 62 76.7 (75.5–78.0) 9.2 (8.9–9.5) 50 77.1 (75.9–78.2) 9.1 (8.8–9.4)
2 y 52 83.6 (82.8–85.1) 10.5 (10.1–10.9) 63 83.9 (82.3–85.6) 10.7 (10.3–11.1)
Month 36
0 y 15 66.5 (64.9–68.1) 7.4 (7.0–7.9) 15 66.0 (64.5–67.5) 7.3 (6.8–7.7)
1 y 52 74.9 (73.6–76.1) 8.9 (8.5–9.2) 28 75.8 (73.9–77.6) 8.9 (8.5–9.3)
2 y 44 84.8 (82.9–86.7) 10.8 (10.4–11.3) 52 83.7 (82.5–85.0) 10.8 (10.4–11.1)
3 y 64 93.7 (92.1–95.2) 12.7 (12.3–13.1) 62 91.7 (90.3–93.0) 12.4 (12.0–12.9)
4 y 60 99.6 (98.2–101.0) 14.3 (13.9–14.7) 63 99.2 (97.9–100.5) 14.3 (13.9–14.7)
https://doi.org/10.1371/journal.pntd.0007442.t004
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imbalance of ages in the two groups. This study was cluster-randomized since it was per-
formed in the context of community antibiotic treatments for trachoma. An individually ran-
domized trial could have been powered to detect an even smaller difference between children
treated with and without antibiotics. On the other hand, the cluster-randomization better
approximates the effectiveness of programmatic azithromycin and allows for the possibility of
both direct and spillover effects of antibiotics.[12] Finally, this study was conducted in a region
of Ethiopia with hyperendemic trachoma that had already received several rounds of mass azi-
thromycin distributions. The generalizability of the findings to an antibiotic-naïve population
or a population with milder or no trachoma is unclear.
In conclusion, mass azithromycin distributions have proven extremely effective at reducing
the burden of ocular chlamydia and may also have important ancillary benefits, like reducing
the prevalence of respiratory infections, diarrhea, malaria, and skin infections—as well as
childhood deaths.[9–11, 32] Although we hypothesized that childhood growth promotion
might be an additional benefit of mass azithromycin distributions, the present study was
unable to provide strong evidence of such an association.
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